General Information - Additional Information (Detail) - Subsidiary |
6 Months Ended | ||
|---|---|---|---|
Aug. 11, 2025 |
Apr. 16, 2024 |
Jun. 30, 2026 |
|
| Disclosure Of General Information About Financial Statements [Abstract] | |||
| Description of nature of entity's operations | clinical-stage biopharmaceutical company developing a portfolio of new medicines to treat patients with cancer | ||
| Name of reporting entity | NuCana plc | ||
| Domicile of entity | United Kingdom | ||
| Country of incorporation | England and Wales | ||
| Number of subsidiaries | 3 | ||
| Name of subsidiary | NuCana, Inc., NuCana Limited and NuCana BioMed Trustee Company Limited | ||
| Description of change In ratio of shares | one ADS representing 25 ordinary shares, to one ADS representing 5,000 ordinary shares. | from one ADS representing one ordinary share, to one ADS representing 25 ordinary shares. |
| X | ||||||||||
- Definition The country in which the entity is incorporated. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The description of the nature of the entity's operations and principal activities. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The country of domicile of the entity. [Refer: Country of domicile [member]] Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The name of the reporting entity or other means of identification. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The name of a subsidiary. [Refer: Total for all subsidiaries [member]] Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Description of change in ratio of shares. No definition available.
|
| X | ||||||||||
- Definition Disclosure of general information about financial statements [abstract] No definition available.
|
| X | ||||||||||
- Definition Number of subsidiaries. No definition available.
|